三生製藥(01530.HK)公布，公司向國家藥品監督管理局提交的三生製藥重組人血小板生成素注射液(特比澳)新適應症已獲得批准，用於治療兒童或青少年的持續性或慢性原發免疫性血小板減少症。
特比澳是三生製藥自主研製的重組人血小板生成素注射液，此前已獲批成人實體瘤化療後血小板減少症和成人原發免疫性血小板減少症適應 症。
三生製藥(01530.HK)特比澳新適應症申請獲批
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.